Abstract P6-07-10: DNA methylation signature predicting bevacizumab efficacy in metastatic breast cancer
ConclusionsEarly results from this multi-center trial demonstrate that IORT using the Xoft Axxent eBx System at the time of breast conservation surgery continues to be a promising treatment option for early stage breast cancer. The short course of radiation therapy for select patients has excellent to good cosmetic results and a low rate of high-grade adverse events and recurrences.FundingFunded by Xoft, Inc., a subsidiary of iCAD, Inc.AcknowledgementMedical writing support from Dr. Theresa E. Singleton, Singleton Science, LLC.Citation Format: Gampenrieder SP, Rinnerthaler G, Pulverer W, Weinhäusel A, Hufnagl C, Hackl H, Hauser-Kronberger C, Mlineritsch B, Greil R. DNA methylation signature predicting bevacizumab efficacy in metastatic breast cancer [abstract]. In: Proceedings of the Thirty-Ninth Annual CTRC-AACR San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-07-10.
Source: Cancer Research - Category: Cancer & Oncology Authors: SP Gampenrieder, G Rinnerthaler, W Pulverer, A Weinhausel, C Hufnagl, H Hackl, C Hauser–Kronberger, B Mlineritsch, R Greil Tags: Poster Session Abstracts Source Type: research
More News: Avastin | Brachytherapy | Breast Cancer | Breast Carcinoma | Breast Conservation Surgery | Breast Lumpectomy | Cancer | Cancer & Oncology | Carcinoma | Carcinoma in Situ | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | Harvard | Lumpectomy | Pain | Radiation Therapy | Science | Skin | Skin Biopsy | Study | Ultrasound